***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Although , as yet , there is no specific treatment of epidermolysis bullosa ( EB ) simplex , anecdotal reports suggest the possible efficacy of one of the newer topical nonsteroidal anti-inflammatory agents , bufexamac . To determine whether bufexamac has any role in the management of this disease , a double-blind placebo-controlled crossover clinical trial was undertaken with ten patients ( nine , Weber-Cockayne variant ; one , generalized EB simplex ) . Each of the two preparations was applied four times daily during the 2 four-week treatment periods . Weekly assessment s included counts of blisters , crusts , and erosions , and assessment s of alterations in cutaneous pain , healing times , and activity times before further blister formation . Although considerable variability in individual responses was noted , no significant difference was detectable between the active drug and its matched placebo . On the basis of these findings , it was concluded that 5 % topical bufexamac is ineffective in the treatment of EB simplex BACKGROUND Recessive dystrophic epidermolysis bullosa is an uncommon , severely disabling , heritable disorder characterized by abnormal fragility of the skin . Open trials have suggested that phenytoin is an effective treatment , and this therapy is now widely used . METHODS To determine the efficacy of phenytoin in the treatment of recessive dystrophic epidermolysis bullosa , we performed a r and omized , double-blind , placebo-controlled , crossover trial in 36 patients . Each treatment was given for five to seven months , separated by a two-month period . We measured the total number of blisters and erosions on the entire body , the size of three plaques containing blisters and erosions , and the number of blisters and erosions in the three plaques at the beginning and end of each treatment period in each patient . RESULTS Twenty-two patients completed both courses of therapy , seven patients completed one course , and seven patients withdrew before completing a single course . There was no significant difference in disease activity between phenytoin treatment and placebo treatment , as measured by changes in the number of blisters and erosions on the entire body ( 7 percent decrease vs. 6 percent increase ) , in the area of three design ated plaques ( 0.4 percent decrease vs. 0.2 percent increase ) , or in the number of blisters and erosions in the design ated plaques ( 12 percent decrease vs. 31 percent increase ) . CONCLUSIONS Phenytoin is not an effective treatment for patients with recessive dystrophic epidermolysis bullosa 
    Output:
    
There is no reliable trial evidence for interventions in inherited EB .